{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:07:41Z","timestamp":1778825261166,"version":"3.51.4"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["VANCIT23AO-LAD"],"award-info":[{"award-number":["VANCIT23AO-LAD"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["NELSON20QI0"],"award-info":[{"award-number":["NELSON20QI0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.jcf.2025.04.010","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T22:52:49Z","timestamp":1746312769000},"page":"652-659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Physical well-being and burden of care in adults on modulator therapy: A mixed methods study of patient-reported experiences from the Well-ME survey"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4057-0561","authenticated-orcid":false,"given":"Cynthia D.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7796-8720","authenticated-orcid":false,"given":"Carla","family":"Frederick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4817-5785","authenticated-orcid":false,"given":"Emily","family":"Zagnit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel R.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2961-5661","authenticated-orcid":false,"given":"Aricca D.","family":"Van Citters","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2025.04.010_bib0001","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","article-title":"Clinical Effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in People with Cystic Fibrosis: a Clinical Trial","volume":"205","author":"Nichols","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.04.010_bib0002","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jcf.2025.04.010_bib0003","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S2213-2600(23)00324-7","article-title":"Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy","volume":"11","author":"Hisert","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.04.010_bib0004","series-title":"2023 Annual data report","year":"2024"},{"key":"10.1016\/j.jcf.2025.04.010_bib0005","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.jcf.2023.04.008","article-title":"Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1\/2 clinical study","volume":"22","author":"Rowe","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0006","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S2213-2600(22)00504-5","article-title":"Safety and efficacy of vanzacaftor-tezacaftor-deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials","volume":"11","author":"Uluer","year":"2023","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jcf.2025.04.010_bib0007","first-page":"14","article-title":"The Assessment and Measurement of Wellness in the Clinical Medical Setting: a Systematic Review","volume":"15","author":"Bart","year":"2018","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.jcf.2025.04.010_bib0008","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/thoraxjnl-2015-207488","article-title":"International Committee on Mental Health in Cystic Fibrosis: cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus statements for screening and treating depression and anxiety","volume":"71","author":"Quittner","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2025.04.010_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.04.010_bib0010","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.04.010_bib0011","article-title":"Wellness in the modulator era: an observational study of the impact of CFTR modulator therapy on the well-being of people with cystic fibrosis","author":"Van Citters","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0012","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1007\/s11136-009-9496-9","article-title":"Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items","volume":"18","author":"Hays","year":"2009","journal-title":"Qual Life Res"},{"key":"10.1016\/j.jcf.2025.04.010_bib0013","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s11606-015-3290-x","article-title":"General Population Estimate for \u201cExcellent\u201d to \u201cPoor\u201d Self-Rated Health Item","volume":"30","author":"Hays","year":"2015","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.jcf.2025.04.010_bib0014","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner","year":"2007","journal-title":"Psychiatry (Edgmont)"},{"key":"10.1016\/j.jcf.2025.04.010_bib0015","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jcf.2025.04.010_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.02.001","article-title":"Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis","author":"Zemanick","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0017","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2025.04.010_bib0018","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jcf.2023.10.001","article-title":"Reduction in abdominal symptoms (CFAbd-Score), faecal M2-pyruvate-kinase and Calprotectin over one year of treatment with Elexacaftor-Tezacaftor-Ivacaftor in people with CF aged >\/=12 years - The RECOVER study","volume":"23","author":"Mainz","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0019","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2022.10.003","article-title":"Elexacaftor\/tezacaftor\/ivacaftor and gastrointestinal outcomes in cystic fibrosis: report of promise-GI","volume":"22","author":"Schwarzenberg","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0020","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.jcf.2024.07.013","article-title":"Estimating minimal clinically important difference (MCID) for gastrointestinal symptoms in cystic fibrosis","volume":"23","author":"Lee","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0021","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1136\/thorax-2023-220100","article-title":"A refresh of the top 10 research priorities in cystic fibrosis","volume":"78","author":"Rowbotham","year":"2023","journal-title":"Thorax"},{"key":"10.1016\/j.jcf.2025.04.010_bib0022","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/1479972316631135","article-title":"Pain and its clinical associations in individuals with cystic fibrosis: a systematic review","volume":"13","author":"Lee","year":"2016","journal-title":"Chron Respir Dis"},{"key":"10.1016\/j.jcf.2025.04.010_bib0023","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jcf.2022.08.006","article-title":"Prevalence of unmet pain and symptom management needs in adults with cystic fibrosis","volume":"22","author":"Dubin","year":"2023","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0024","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jpainsymman.2016.03.023","article-title":"The Association Between Pain and Clinical Outcomes in Adolescents With Cystic Fibrosis","volume":"52","author":"Lechtzin","year":"2016","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.jcf.2025.04.010_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.12.004","article-title":"Pain is a constant in our lives with CF: please believe us","author":"Elshaar","year":"2025","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0026","article-title":"Addressing pain in people living with cystic fibrosis: cystic fibrosis foundation evidence-informed guidelines","author":"Dellon","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0027","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.pmn.2017.11.011","article-title":"Descriptions of the Pain Experience in Adults and Adolescents with Cystic Fibrosis","volume":"19","author":"Allgood","year":"2018","journal-title":"Pain Manag Nurs"},{"key":"10.1016\/j.jcf.2025.04.010_bib0028","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.jcf.2024.03.005","article-title":"Symptoms and quality of life in adults with cystic fibrosis: a cross-sectional analysis of the InSPIRe:CF trial","volume":"23","author":"Smirnova","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0029","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","article-title":"High treatment burden in adults with cystic fibrosis: challenges to disease self-management","volume":"8","author":"Sawicki","year":"2009","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0030","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jcf.2018.11.010","article-title":"Beyond the expected: identifying broad research priorities of researchers and the cystic fibrosis community","volume":"18","author":"Hollin","year":"2019","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0031","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.chest.2022.07.008","article-title":"Treatment Preference Among People With Cystic Fibrosis: the Importance of Reducing Treatment Burden","volume":"162","author":"Cameron","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.jcf.2025.04.010_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.09.011","article-title":"Cystic fibrosis foundation position paper: redefining the cystic fibrosis care team","author":"Brown","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2024.09.002","article-title":"Adapting the cystic fibrosis care model: perspectives from people with CF, caregivers, and members of CF care teams","author":"Tran","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0034","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/j.jcf.2024.08.007","article-title":"Cystic fibrosis foundation position paper: redefining the CF care model","volume":"23","author":"Goetz","year":"2024","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2025.04.010_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2025.01.001","article-title":"Impact of CFTR modulator therapy on basic life needs and financial concerns in people with cystic fibrosis: data from the Well-ME survey","author":"Boas","year":"2025","journal-title":"J Cyst Fibros"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199325014651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:14:35Z","timestamp":1778822075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199325014651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1569199325014651"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2025.04.010","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physical well-being and burden of care in adults on modulator therapy: A mixed methods study of patient-reported experiences from the Well-ME survey","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2025.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}